Suppr超能文献

十年来血管内治疗对非破裂性腹主动脉瘤修复术后住院死亡率的影响:一项基于16446例患者的人群研究。

The impact of endovascular treatment on in-hospital mortality following non-ruptured AAA repair over a decade: a population based study of 16,446 patients.

作者信息

Akkersdijk G J M, Prinssen M, Blankensteijn J D

机构信息

Department of Surgery, Spaarne Hospital, Haarlem, The Netherlands.

出版信息

Eur J Vasc Endovasc Surg. 2004 Jul;28(1):41-6. doi: 10.1016/j.ejvs.2004.01.003.

Abstract

OBJECTIVES

We hypothesised that over the past decade, the nation-wide outcome of infrarenal abdominal aortic aneurysm (AAA) repair has improved with the introduction of endovascular treatment. The aim of the study was to identify endovascularly-treated patients in a national registry and to assess the impact on in-hospital mortality of non-ruptured AAA repair, if any, after the introduction of endovascular repair.

MATERIALS AND METHODS

We retrospectively studied the nation-wide outcome of non-ruptured AAA repair over the past decade. Variables studied were age and gender of the patients, hospital size and type and the year in which treatment was performed and the outcome on in-hospital mortality. The in-hospital mortality of non-ruptured AAA repair in 16,446 patients in the 10-year period from 1991 to 2000 was 7.3% (6.2-8.2%). In the 15,589 (95%) patients that underwent conventional treatment, in-hospital mortality was 7.6% (7.0-8.1%), whereas in the endovascular group it was 1.9% (0.6-3.5%). In the multivariate analysis, age and endovascular repair were the most important independent predictors of in-hospital mortality.

CONCLUSION

With the limitations of a national registry aside, the introduction of endovascular aneurysm repair seems to have had a small but significant impact on in-hospital mortality following infrarenal AAA repair.

摘要

目的

我们推测,在过去十年中,随着血管内治疗的引入,肾下腹主动脉瘤(AAA)修复的全国性结果有所改善。本研究的目的是在全国登记处识别接受血管内治疗的患者,并评估血管内修复引入后对非破裂性AAA修复的院内死亡率的影响(若有)。

材料与方法

我们回顾性研究了过去十年中全国范围内非破裂性AAA修复的结果。研究的变量包括患者的年龄和性别、医院规模和类型、治疗年份以及院内死亡率结果。1991年至2000年这10年间,16446例患者的非破裂性AAA修复的院内死亡率为7.3%(6.2 - 8.2%)。在接受传统治疗的15589例(95%)患者中,院内死亡率为7.6%(7.0 - 8.1%),而血管内治疗组为1.9%(0.6 - 3.5%)。在多变量分析中,年龄和血管内修复是院内死亡率最重要的独立预测因素。

结论

撇开全国登记处的局限性不谈,血管内动脉瘤修复的引入似乎对肾下AAA修复后的院内死亡率产生了虽小但显著的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验